

THE WHITE HOUSE WASHINGTON

# COVID-19 Press Briefing


August 31, 2021



## Daily Change in COVID-19 Cases, US

January 22, 2020 – August 29, 2021

TOTAL Cases Reported Since 1/22/20 38,852,582 NEW Cases Reported to CDC on 8/29/21 42,329 Change in 7-Day Case Average -10.5% Current 7-Day Case Average (8/23/21 - 8/29/21) 129,418 Prior 7-Day Case Average (8/16/21 - 8/22/21) 144,614



\*7-day averages exclude historical cases reported retroactively by states



## New Admissions of Patients with Confirmed COVID-19, US

#### August 1, 2020 – August 28, 2021

#### Patients Currently Hospitalized with COVID on 8/28/21

58,997

New Admissions on 8/28/21

8,244

Peak in New Admissions (1/5/21)

17,963


Change in 7-Day Average of New Admissions

```
-4.8%
```

```
Current 7-Day Average of New Admissions (8/22/21 - 8/28/21)
11,533
```

```
Prior 7-Day Average of New Admissions (8/15/21 - 8/21/21)
```

#### 12,117




• Latest • New Admissions • Recent Low — 7-Day Moving Average - New Admissions



## Daily Change in COVID-19 Deaths, US

January 22, 2020 – August 29, 2021





# Update on COVID-19 Vaccination in Pregnancy





## **COVID-19 in Pregnancy is Associated with Adverse Outcomes for Mother and Baby**

## **The Importance of Vaccination**





Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

November 6, 2020

#### Morbidity and Mortality Weekly Report (MMWR)

Volume 69, Number 44

Presente al state sentie (DD)

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020

Analysis of ~400,000 women aged 15–44 years with symptomatic COVID-19

Though absolute numbers are small, increased risk among pregnant women (versus non-pregnant women) for

	<u>Adjusted risk ratio (RR)</u>
<ul> <li>Intensive care unit admission</li> </ul>	3.0
<ul> <li>Invasive ventilation</li> </ul>	2.9
<ul> <li>Extracorporeal membrane oxygenation</li> </ul>	2.4
– Death	1.5



### Pregnant Women with COVID-19, United States, January 22, 2020 – August 23, 2021



Hospitalized cases\* 18,639

Total deaths

131

\*Data were collected from 109,773 women, but hospitalization data were only available for 87,509 (79.7%) Source: CDC, https://covid.cdc.gov/covid-data-tracker/#pregnant-population






Risk Factors for Illness Severity Among Pregnant Women With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 Infection—Surveillance for Emerging Threats to Mothers and Babies Network, 22 State, Local, and Territorial Health Departments, 29 March 2020–5 March 2021

RR Galang et al. for the CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team

Among 7,950 pregnant women with SARS-CoV-2 infection, moderate-to-severe or critical COVID-19 illness was associated with age 25 years and older, healthcare occupation, pre-pregnancy obesity, chronic lung disease, chronic hypertension, and pregestational diabetes mellitus. Risk of moderate-to-severe or critical illness increased with the number of underlying medical or pregnancy-related conditions.





### Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

TT Shimabukuro, DM Meaney-Delman et al. for the CDC v-safe COVID-19 Pregnancy Registry Team\*

35,691 v-safe participants identified as pregnant

No obvious safety signals among pregnant persons who received mRNA Covid-19 vaccines.





## Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women

A-RY Collier, DH Barouch et al.

- COVID-19 mRNA vaccines generated potent antibody and T-cell responses in pregnant, lactating and non-pregnant women, and in infant cord blood and breast milk
- Consistent with previous studies, vaccination elicited higher antibody responses than infection
- Pregnant and nonpregnant vaccinated women developed cross-reactive immune responses against SARS-CoV-2 variants of concern.





## SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

SH Perl, I Youngster et al.

- Robust secretion of SARS-CoV-2 specific IgA and IgG antibodies in breast milk for 6-week follow up period after vaccination
- Antibodies found in breast milk of these women showed strong neutralizing effects, suggesting a potential protective effect against infection in the infant



### Statement of Strong Medical Consensus for Vaccination of Pregnant Individuals Against COVID-19

August 9, 2021

American College of Obstetricians and Gynecologists I American Academy of Family Physicians I American Academy of PAs I American Academy of Pediatrics I American Association of Nurse Practitioners I American College of Nurse-Midwives I American College of Osteopathic Obstetricians & Gynecologists I American College of Physicians I American Pharmacists Association I Association of Immunization Managers I Association of State and Territorial Health Officials I Association of Women's Health, Obstetric and Neonatal Nurses I Infectious Diseases Society of America I Infectious Diseases Society for Obstetrics and Gynecology I National Association of Chain Drug Stores I National Association of County & City Health Officials I National Association of Nurse Practitioners in Women's Health I National Foundation for Infectious Diseases I National Hispanic Medical Association I North American Society for Pediatric and Adolescent Gynecology I Society for Maternal-Fetal Medicine I Society of OB/GYN Hospitalists I Vaccinate Your Family

### 23 leading organizations

"...we strongly urge all pregnant individuals—along with recently pregnant, planning to become pregnant, lactating and other eligible individuals—to be vaccinated against COVID-19."





THE WHITE HOUSE WASHINGTON

